Early Phase Development

mRNA Vaccine Produces Immune and T-cell Response

July 21, 2020

Preliminary data from a German Phase I/II trial shows Pfizer/BioNTech COVID-19 vaccine candidate produces immune response.

AstraZeneca Vaccine Shows Antibody and T-cell responses

July 20, 2020

Strong immune response by patients receiving two doses of vaccine suggests a possible treatment strategy.

SGS Initiates Clinical Trial of Biophytis’ Treatment for COVID-19 Related Respiratory Failure

July 08, 2020

SGS has announced the receipt of approval from Belgium’s Federal Agency for Medicines and Health Products (FAMHP) to begin a new clinical trial of a potential treatment for patients with COVID-19 related respiratory failure.

GSK, Medicago Collaborate on Covid-19 Vaccine Candidate

July 08, 2020

GlaxoSmithKline (GSK) and Medicago have announced a collaboration for the development and evaluation of a COVID-19 vaccine candidate.

EDQM Publishes New General Chapter in European Pharmacopoeia Supplement 10.3

July 07, 2020

The European Directorate for the Quality of Medicines and Healthcare (EDQM) has published a new general chapter (2.6.32) in the European Pharmacopoeia (Ph. Eur.) supplement 10.3.

Can Using RNA Simplify Gene Therapy Development?

July 02, 2020

BioPharm International

RNA is easier to manipulate than DNA but challenging to deliver to the right cells.

ILC Therapeutics Enters Research Agreement with University of St Andrews

June 25, 2020

Biotechnology company, ILC Therapeutics, has revealed that it has entered into a research partnership with the University of St Andrews aimed at progressing a therapeutic drug that can treat COVID-19 to clinical trials.

Atriva Therapeutics Announces Clinical Strategy to Treat COVID-19 Patients

May 28, 2020

Biopharmaceutical company, Atriva Therapeutics, has announced, in a May 28, 2020 press release, that it will develop ATR-002, an oral small molecule, for treatment of patients with moderate-to-severe COVID-19 that require hospitalization in a Phase II study.

How Fast Is Too Fast?

May 01, 2020

BioPharm International

Will moving at “warp speed” to develop a vaccine impact efficacy or safety?

NIAID Plan Describes COVID-19 Research Priorities

April 24, 2020

A new strategic plan from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, details the institute’s plan for accelerating research to diagnose, prevent and treat COVID-19.